Friday, 25 October 2013

Activated CB1 Receptor: New Study Shows Cannabinoids Might Prevent Prostate Cancer



A recent study out of Madrid Spain and published by the US National Institute of Health is offering hope for those who suffer from prostate cancer. Utilizing a compound meant to imitate the medical effects of marijuana’s cannabinoids, researchers discovered that by activating the body’s own natural cannabinoid receptors – a naturally occurring event when cannabis is consumed – can prevent, and treat hormone sensitive prostate cancer.

While prostate cancer is predominantly an issue for older men – over the age of 65, men with a family history of prostate cancer stand a greater risk of being diagnosed as early as their late 30s, or early 40s.

According to Instituto de Química Médica’s;

“Chromenopyrazolediones have been designed and synthesized as anticancer agents using the multi-biological target concept that involves quinone cytotoxicity and cannabinoid antitumor properties. In cell cytotoxicity assays, these chromenopyrazolediones have antiproliferative activity against human prostate cancer and hepatocellular carcinoma. It has been shown that the most potent, derivative 4 (PM49), inhibits prostate LNCaP cell viability (IC50 = 15 μM) through a mechanism involving oxidative stress, PPARγ receptor and partially CB1 receptor. It acts on prostate cell growth by causing G0/G1 phase arrest and triggering apoptosis as assessed by flow cytometry measurements. In the in vivo treatment, compound 4 at 2 mg/kg, blocks the growth of LNCaP tumors and reduces the growth of PC-3 tumors generated in mice. These studies suggest that 4 is a good potential anticancer agent against hormone-sensitive prostate cancer.”

The conclusion of this study is that marijuana’s cannabinoids represent a; “good potential anticancer agent against hormone sensitive prostate cancer.”

Great news to end the week…